Green Fabrication of Berberine Nano Lipid Carriers by Hot Melt-ultrasonication Method

Van Nguyen ( Life Sciences department, University of Science and Technology of Ha Noi, A21 building, Vietnam Academy of Science and Technology, 18 Hoang Quoc Viet, Cau Giay, Hanoi, Vietnam. )

Vy Nguyen Thuy ( Life Sciences department, University of Science and Technology of Ha Noi, A21 building, Vietnam Academy of Science and Technology, 18 Hoang Quoc Viet, Cau Giay, Hanoi, Vietnam. )

Hien Dang Thi ( Faculty of Pharmacy, Phenikaa University, Yen Nghia Ward, Ha Dong District, Hanoi, Vietnam. )

https://doi.org/10.37155/2972-483X-SI-5

This Article Belongs To The Special Issue: Sustainable Process Engineering: Collaborations between Industry and Academia

Abstract

The purpose of this research was to examine several factors such as lipids, surfactants and their own lipids were the blend of glyceryl monostearate with glyceryl dibehenate (C888), liquid lipid was Miglyol 812N (M812). Non-ionic hydrophilic surfactant-Poloxamer 407 was found to be suitable to provide nanostructure than its counterpart -Tween 80 (Tw 80). The in vitro drug dissolution was following oral administration model, through a dialysis bag, with the media of phosphate buffer pH 6.8, apparatus 2 at the speed of 50 rpm. As a result, NLCs were successfully fabricated from C888, M812 and P407. The value of hydrophilic-lipophilic balance should be from18 to 22 to ensure favourable preparation of BBR-NLCs. 15% liquid lipid over total used lipid (w/w) was shown best BBR encapsulation. The more liquid lipid quantity, the larger the particle size. In general, the best BBR-NLCs had a size of 102.30nm ± 5.49nm, uniform distribution, entrapment efficiency of 85% ± 0.96% and total release of nearly 70% after 24 hours, which was more sustained release than pure drug solution. The stability test proved BBR-NLCs could be considered as stable in nearly 30-day storage at room condition.

 

Keywords

Berberine; Nano lipid carrier; Ultrasonication; Hot - melt

Full Text

PDF

References

[1]. Chander, V., et al., A review on Pharmacological potential of Berberine; an active component of Himalayan Berberis aristata. J Phytopharmacol, 2017. 6(1): p. 53-58.
[2]. Battu, S.K., et al., Physicochemical characterization of berberine chloride: a perspective in the development of a solution dosage form for oral delivery. AAPS PharmSciTech, 2010. 11(3): p. 1466-1475.
[3]. Imenshahidi, M. and H. Hosseinzadeh, Berberine and barberry (Berberis vulgaris): a clinical review. Phytotherapy Research, 2019. 33(3): p. 504-523.
[4]. Muluye, R.A., Y. Bian, and P.N. Alemu, Anti-inflammatory and antimicrobial effects of heat-clearing Chinese herbs: a current review. Journal of traditional and complementary medicine, 2014. 4(2): p. 93-98.
[5]. Tan, J., et al., Antimicrobial characteristics of Berberine against prosthetic joint infection-related Staphylococcus aureus of different multi-locus sequence types. BMC Complementary and Alternative Medicine, 2019. 19(1): p. 218.
[6]. Zhang, Y., et al., Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). Nature communications, 2020. 11(1): p. 1-12.
[7]. Warowicka, A., R. Nawrot, and A. Goździcka-Józefiak, Antiviral activity of berberine. Arch Virol, 2020. 165(9): p. 1935-1945.
[8]. Zhang, C., et al., Effects of Berberine and Its Derivatives on Cancer: A Systems Pharmacology Review. Frontiers in Pharmacology, 2020. 10: p. 1461.
[9]. Yasir, M., et al., Biopharmaceutical classification system: An account. International Journal of PharmTech Research, 2010. 2(3): p. 1681-1690.
[10]. Fundarò, A., et al., Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after iv administration to rats. Pharmacological Research, 2000. 42(4): p. 337-343.
[11]. Makoni, P.A., K. Wa Kasongo, and R.B. Walker, Short Term Stability Testing of Efavirenz-Loaded Solid Lipid Nanoparticle (SLN) and Nanostructured Lipid Carrier (NLC) Dispersions. Pharmaceutics, 2019. 11(8): p. 397.
[12]. Deng, J., et al., Berberine-Loaded Nanostructured Lipid Carriers Enhance the Treatment of Ulcerative Colitis. International journal of nanomedicine, 2020. 15: p. 3937-3951.
[13]. Yin, J., et al., Selenium-coated nanostructured lipid carriers used for oral delivery of berberine to accomplish a synergic hypoglycemic effect. International journal of nanomedicine, 2017. 12: p. 8671-8680.
[14]. Lohan, S., et al., Galactosylated nanoconstructs of Berberine with enhanced Biopharmaceutical and cognitive potential: A preclinical evidence in Alzheimer ‘s disease. Journal of Drug Delivery Science and Technology, 2021. 66: p. 102695.
[15]. Raju, M., et al., Berberine loaded nanostructured lipid carrier for Alzheimer's disease: Design, statistical optimization and enhanced in vivo performance. Life Sciences, 2021. 285: p. 119990.
[16]. Nguyen, V.H., K.N. Manh Le, and M.C.N. Nguyen, Spray-dried solid lipid nanoparticles for enhancing berberine bioavailability via oral administration. Current Pharmaceutical Design, 2023. 29(38): p. 3050-3059.
[17]. Aburahma, M.H. and S.M. Badr-Eldin, Compritol 888 ATO: a multifunctional lipid excipient in drug delivery systems and nanopharmaceuticals. Expert opinion on drug delivery, 2014. 11(12): p. 1865-1883.
[18]. Jenning, V., M. Schäfer-Korting, and S. Gohla, Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. Journal of Controlled Release, 2000. 66(2): p. 115-126.
[19]. Grumezescu, A.M., Design of nanostructures for versatile therapeutic applications. 2018: William Andrew.
[20]. Bodratti, A.M. and P. Alexandridis, Formulation of Poloxamers for Drug Delivery. Journal of functional biomaterials, 2018. 9(1): p. 11.
[21]. Han, F., et al., Effect of surfactants on the formation and characterization of a new type of colloidal drug delivery system: nanostructured lipid carriers. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2008. 315(1-3): p. 210-216.
[22]. Ici Americas, i., The HLB system : a time-saving guide to emulsifier selection. 1984, Wilmington: ICI Americas, Inc.
[23]. Lieberman, H., M. Rieger, and G.S. Banker, Pharmaceutical dosage forms: Disperse systems. 2020: CRC Press.
[24]. Fitriani, E.W., et al., Development of nanostructured lipid carrier containing tea tree oil: Physicochemical properties and stability. Journal of Pharmacy & Pharmacognosy Research, 2023. 11(3): p. 391-400.
[25]. Ortiz, A.C., et al., Development of a nanostructured lipid carrier (NLC) by a low-energy method, comparison of release kinetics and molecular dynamics simulation. Pharmaceutics, 2021. 13(4): p. 531.
[26]. Khosa, A., S. Reddi, and R.N. Saha, Nanostructured lipid carriers for site-specific drug delivery. Biomedicine & Pharmacotherapy, 2018. 103: p. 598-613.
[27]. Patel, S.G., et al., Chapter 8 - Solid Lipid Nanoparticles for Targeted Brain Drug Delivery, in Nanotechnology-Based Targeted Drug Delivery Systems for Brain Tumors, P. Kesharwani and U. Gupta, Editors. 2018, Academic Press. p. 191-244.
[28]. Chaudhari, V.S., U.S. Murty, and S. Banerjee, Nanostructured lipid carriers as a strategy for encapsulation of active plant constituents: Formulation and in vitro physicochemical characterizations. Chemistry and Physics of Lipids, 2021. 235: p. 105037.
[29]. Shrivastava, S., B. Gidwani, and C.D. Kaur, Development of mebendazole loaded nanostructured lipid carriers for lymphatic targeting: Optimization, characterization, in-vitro and in-vivo evaluation. Particulate Science and Technology, 2021. 39(3): p. 380-390.
[30]. Müller, R.H., M. Radtke, and S.A. Wissing, Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Advanced Drug Delivery Reviews, 2002. 54: p. S131-S155.

Copyright © 2025 Van Nguyen, Vy Nguyen Thi Thuy, Hien Dang Thi Creative Commons License Publishing time:2025-04-18
This work is licensed under a Creative Commons Attribution 4.0 International License